Sökning: WFRF:(Eriksson Marie Professor)
> (2005-2009) >
Cytomegalovirus Inf...
Cytomegalovirus Infection in Immunocompetent and Renal Transplant Patients : Clinical Aspects and T-cell Specific Immunity
-
- Sund, Fredrik, 1969- (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Eriksson, Britt-Marie, MD (preses)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Korsgren, Olle, Professor (preses)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
-
visa fler...
-
- Rollag, Halvor, Professor (opponent)
- Dept. of Virology
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789155473099
- Uppsala : Acta Universitatis Upsaliensis, 2008
- Engelska 87 s.
-
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 386
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://uu.diva-port...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Cytomegalovirus (CMV) is a β-herpesvirus that, after primary infection, establishes a life-long persistence in the human host. Up to 90% of humans are infected with CMV, that is kept under control by CMV-specific CD8+ and CD4+ T cells. In patients with an impaired cellular immunity, however, CMV infections can be life-threatening. Thus, it is vital to identify risk factors and target high-risk patients. In this thesis we have evaluated low-dose valacyclovir prophylaxis in renal transplant patients and studied CMV-specific T cell immunity in healthy and renal transplant patients. In renal transplant patients, the CMV serostatus of both the recipient (R) and the donor (D) has a major impact on the risk of developing CMV disease. In the high-risk D+/R- population, >50% are likely to develop CMV disease in the absence of prophylaxis and/or pre-emptive therapy. We have used low-dose valacyclovir prophylaxis for high-risk renal transplant patients, and graft and patient survival up to 5 years after transplantation was comparable to data reported for other prophylactic protocols. The incidence of CMV disease and graft rejection during the first year after transplantation was also comparable to that achieved with other protocols, and without the adverse effects reported for other therapies. In the D+/R+ population, with a 15-35% risk of developing CMV disease, it is important to identify those individuals that are subject to a higher risk because of risk factors other than CMV serostatus. We therefore measured several immunologic parameters in renal transplant patients and in immunocompetent individuals with latent and primary CMV infection. In patients with a primary symptomatic CMV infection, CMV-specific CD8+ T cells peaked within a month after onset of symptoms but declined rapidly. In renal transplant patients, we found that the reduction in IFNγ-producing CMV-specific CD4+ T cells at 2 months post-transplantation may predict high-grade CMV DNAemia.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- Cytomegalovirus
- renal transplantation
- cellular immunity
- valacyclovir
- mismatched
- prophylaxis
- tetramer
- CD4 T cells
- CD8 T cells
- Infectious diseases
- Infektionssjukdomar
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas